Skip to content
Head to head

Iovance Biotherapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: IOVA · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

IOVA +185.1%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
IOVAVRTX
Snapshot
Sector--Biotechnology
Last price6.90515.02
Change today-5.61%-1.08%
1-year return+216.5%+22.0%
Market cap$3.19B$130.58B
52-week range2.08 – 15.37412.27 – 568.67
Valuation
P/E (TTM)-14.0833.14
P/E percentile, own 5-yr range2nd99th
P/B3.936.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.0915.32
Net profit (TTM)$-504.29M$3.88B
Revenue (TTM)$378.98M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+80.1%+11.8%
Gross margin53.2%85.5%
Operating margin-60.8%33.1%
Net margin-58.2%30.7%
Free cash flow (TTM)$-216.16M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership62.9%96.8%
Insider activity (12mo)30 buy / 20 sell28 buy / 22 sell
Short interest (% of float)14.4%1.9%
Analyst consensus100% buy (8)95% buy / 5% hold (21)
Analyst price target$16 (+137%)$624 (+21%)
StockVane view
StockVane Quant RatingC (99)C (68)
Company
Employees9756,400
Founded20071989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.